<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188265</url>
  </required_header>
  <id_info>
    <org_study_id>HR-95-110</org_study_id>
    <nct_id>NCT01188265</nct_id>
  </id_info>
  <brief_title>Add-on Dextromethorphan in Bipolar Disorders</brief_title>
  <acronym>DM</acronym>
  <official_title>Dextromethorphan Enhances the Therapeutic Efficacy of Valoproate in Bipolar Disorder Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TTY Biopharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dextromethorphan has been reported affording neuroprotection on dopaminergic neurons and&#xD;
      having protective effect against inflammation-related neuron damage. These anti-inflammatory&#xD;
      and neuroprotective effects of dextromethorphan would suggest potential clinical benefits of&#xD;
      dextromethorphan add-on therapy to valproate for bipolar disorder patients. This hypothesis&#xD;
      was based on the findings that the mood stabilizers have been reported to be neuroprotective&#xD;
      through the release of neurotrophic factors such as GDNF from astroglia. Thus, the&#xD;
      combination treatment of mood stabilizers and dextromethorphan might improve the therapeutic&#xD;
      efficacy for bipolar disorder patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Young's Mania Rating Scale (YMRS)</measure>
    <time_frame>baseline, 1, 2, 4, 8 and 12 weeks</time_frame>
    <description>The severity of current manic symptoms will be assessed by using the YMRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS)</measure>
    <time_frame>baseline, 1, 2, 4, 8 and 12 weeks</time_frame>
    <description>The severity of depressive symptoms will be evaluated by HDRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood samples</measure>
    <time_frame>baseline, 1, 2, 4, 8 and 12 weeks</time_frame>
    <description>The immune markers, cytokines will be measured at each time point to follow each patient's changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profiles</measure>
    <time_frame>baseline, after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Valproate &amp; dextromethorphan 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valproate and dextromethorphan 30 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VPA &amp; dextromethorphan 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VPA &amp; dextromethorphan 60 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VPA &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VPA &amp; placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate</intervention_name>
    <arm_group_label>VPA &amp; Placebo</arm_group_label>
    <arm_group_label>VPA &amp; dextromethorphan 60 mg</arm_group_label>
    <arm_group_label>Valproate &amp; dextromethorphan 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan 60 mg per day</intervention_name>
    <description>VPA plus dextromethorphan 60 mg per day</description>
    <arm_group_label>VPA &amp; dextromethorphan 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>VPA plus placebo</description>
    <arm_group_label>VPA &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan 30 mg</intervention_name>
    <description>VPA &amp; Dextromethorphan 30 mg per day</description>
    <arm_group_label>Valproate &amp; dextromethorphan 30 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patient aged ≧18 and ≦65 years.&#xD;
&#xD;
          2. A diagnosis of bipolar I or II disorder according to DSM-IV criteria made by a&#xD;
             specialist in psychiatry.&#xD;
&#xD;
          3. A total of HDRS score at least 18 or YMRS score at least 14 at screen.&#xD;
&#xD;
          4. Signed informed consent by patient or legal representative&#xD;
&#xD;
          5. Patient or a reliable caregiver can be expected to ensure acceptable compliance and&#xD;
             visit attendance for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women of childbearing potential not using adequate contraception as per investigator&#xD;
             judgment or not willing to comply with contraception for duration of study.&#xD;
&#xD;
          2. Females who are pregnant or nursing.&#xD;
&#xD;
          3. Patient has received dextromethorphan, or other selective cyclo- oxygenase 2 (Cox-2)&#xD;
             inhibitors, or other anti-inflammatory medication within 1 week prior to first dose of&#xD;
             double-blind medication.&#xD;
&#xD;
          4. Axis-I DSM-IV diagnosis other than bipolar I or II disorder.&#xD;
&#xD;
          5. Current evidence of an uncontrolled and/or clinically significant medical condition&#xD;
             (e.g., cardiac, hepatic and renal failure), which in the judgments of the&#xD;
             investigator, would compromise patient safety or preclude study participation.&#xD;
&#xD;
          6. History of intolerance to valproate or dextromethorphan or other Cox-2 inhibitors.&#xD;
&#xD;
          7. History of sensitivity reaction (e.g., urticaria, angioedema, bronchospasm, severe&#xD;
             rhinitis, anaphylactic shock) precipitated by dextromethorphan.&#xD;
&#xD;
          8. Patient has received electroconvulsive therapy (ECT) within 4 weeks prior to first&#xD;
             dose of doubleblind medication.&#xD;
&#xD;
          9. Diagnosis of or treatment for esophageal, gastric, pyloric channel, or duodenal&#xD;
             ulceration or related complications (bleeding and/or perforation) within 30 days prior&#xD;
             to receiving first dose of double-blind medication.&#xD;
&#xD;
         10. Inclusion in another bipolar disorder study or study for another indication with&#xD;
             psychotropic's within the last 30 days prior to start of study.&#xD;
&#xD;
         11. Increase in total SGOT, SGPT, BUN and creatinine by more than 3X ULN (upper limit of&#xD;
             normal).&#xD;
&#xD;
         12. History of idiopathic or drug-induced agranulocytosis.&#xD;
&#xD;
         13. Substance-related disorders within 6 months prior to study start, borderline&#xD;
             personality disorder, schizophrenia, or other major psychiatric disorders as defined&#xD;
             by DSM-IV criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ru-Band Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ru-Band Lu</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>August 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2010</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

